Esophageal Cancer Clinical Trials

About Esophageal Cancer trials

Esophageal cancer trial design turns on histology (adenocarcinoma vs squamous cell carcinoma) and a small set of molecular targets that guide treatment selection. HER2 (ERBB2) amplification is present in 15-20% of esophageal and GE junction adenocarcinoma and gates eligibility for anti-HER2 trials, where trastuzumab + chemo + IO is now the post-KEYNOTE-811 standard for HER2-positive adenocarcinoma. PD-L1 (CD274) status, measured by combined positive score (CPS) or tumor proportion score (TPS), gates many IO trials with cutoffs that vary by histology and trial design. FGFR2 amplification is uncommon in esophageal cancer but actionable for FGFR2-targeted trials. MMR deficiency is rare in esophageal cancer but qualifies the small subgroup for immunotherapy trials. EGFR amplification is uncommon but tested for the rare patient who may benefit from EGFR-targeted approaches.

Open esophageal cancer trials sort by histology, stage, and molecular target. Locally advanced trials test additions to or alternatives to the CROSS regimen (carboplatin + paclitaxel + radiation followed by surgery), with adjuvant nivolumab now standard for residual disease after surgery. Adenocarcinoma metastatic first-line trials largely overlap with gastric / GE junction trials, testing chemo + IO + anti-HER2 combinations for HER2-positive disease and chemo + IO for HER2-negative. Squamous cell carcinoma metastatic first-line trials test IO combinations including anti-PD1 + anti-CTLA4 in PD-L1 high disease. Anti-claudin 18.2 trials enroll GE junction adenocarcinoma patients whose tumors test positive for claudin 18.2 (a marker not in this panel but increasingly screened at trial sites). HER2-targeted trials in later lines test ADCs (T-DXd combinations) and bispecifics. ADC trials targeting other antigens are an active later-line space. Organ-preserving trials for locally advanced disease test radiation + IO without surgery for select patients.

When you reach trial screening for esophageal cancer, expect questions about histology, tumor location, HER2 / PD-L1 status, and prior therapy. Histology (adenocarcinoma vs squamous cell carcinoma) and tumor location (cervical, upper, mid, distal esophageal, or GE junction) gate most trials and determine which trial set applies. HER2 status by IHC and FISH for adenocarcinoma trials. PD-L1 CPS or TPS with cutoffs that vary by trial design. MMR / MSI status for IO trials. Prior chemoradiation status and current treatment intent (curative vs palliative). Prior IO exposure for IO-rechallenge or post-IO trials. Prior anti-HER2 exposure for HER2-targeted trials. Performance status, with most trials accepting ECOG 0-1. Adequate nutrition and swallowing function are screened on most esophageal trials because of the disease's impact on intake; some trials require percutaneous feeding tube or parenteral nutrition stability before starting.

Biomarkers tested in Esophageal Cancer trials

These are the molecular markers most commonly required or evaluated in Esophageal Cancer eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.